OVIDHealthcare · BiotechnologyThe 13 Wall Street analysts covering Ovid Therapeutics, Inc. hold a median 12-month price target of $6 — +136.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 66 of 100 as at 31 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Ovid Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (92): The shares have been drifting up relative to others.
Accruals (18): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on OVID, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +136.2% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 Oct 2026 | Wolfe Research | Initiates | Outperform | $5.00 |
| 9 Oct 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 6 Oct 2026 | Guggenheim | Initiates | Buy | $7.00 |
| 6 Oct 2026 | Guggenheim | Initiates | Buy | — |
| 5 Oct 2026 | Guggenheim | Initiates | Buy | $7.00 |
| 5 Oct 2026 | Guggenheim | Initiates | Buy | — |
| 11 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $4.00 → $5.00 |
| 11 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 3 Aug 2026 | Oppenheimer | Maintains | Outperform | — |
| 3 Aug 2026 | Oppenheimer | Maintains | Outperform | $7.00 → $9.00 |
| 15 Apr 2026 | Wedbush | Reiterates | Outperform | — |
| 15 Apr 2026 | Wedbush | Reiterates | Outperform | $7.00 |
| 9 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | $2.00 → $4.00 |
| 9 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 26 Mar 2026 | BTIG | Reiterates | Buy | — |
| 20 Mar 2026 | Wedbush | Maintains | Outperform | — |
| 22 Dec 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 Dec 2025 | LifeSci Capital | Initiates | Outperform | — |
| 11 Dec 2025 | Roth Capital | Initiates | Buy | — |
| 24 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
OVID appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Ovid Therapeutics, Inc. returned +85.4% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 94% of US stocks
Cheaper than 2% of US stocks
Cheaper than 39% of US stocks
Cheaper than 83% of US stocks
Higher than 2% of US stocks
Higher than 4% of US stocks
Higher than 4% of US stocks
Higher than 30% of US stocks
Higher than 29% of US stocks
Higher than 17% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Ovid Therapeutics, Inc. has a market value of $496.1M and an enterprise value of $391.6M.
Revenue in the twelve months to 30 June 2026: $1.6M. The latest quarter shrank 88.3% year on year.
Net income over the same four quarters: −$34.5M, a −2178.9% net margin.
Diluted earnings per share, trailing twelve months: $−0.31.
Free cash flow in the twelve months to 30 June 2026: −$54.8M.
Trailing P/E: −11.0×; forward P/E: −6.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Ovid Therapeutics, Inc. employs 23 people — $69K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Ovid Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Actinium Pharmaceuticals announced that Matt David, M.D., has been appointed Chief Financial Officer.
Why it matters — The announcement concerns Actinium Pharmaceuticals rather than Ovid Therapeutics, so it provides no direct company update for OVID watchers.
Ovid Therapeutics announced that its management will participate in two upcoming investor conferences, including the Cantor Global Healthcare Conference on September 9 at 2:10 pm ET. The announcement was made via GlobeNewsWire on September 3, 2026.
Why it matters — Ovid watchers would care because these conference appearances give investors the opportunity to hear directly from management about the company's brain-disorder programs.
Zacks Investment Research published an article examining whether Ovid Therapeutics (OVID) qualifies as a strong momentum stock pick for investors. The piece evaluates the company's characteristics against momentum-investing criteria.
Why it matters — The article highlights Ovid Therapeutics as a potential momentum stock, which could draw investor attention to the company's current market positioning.
Ovid Therapeutics reported a quarterly loss of $0.08 per share for Q2, which was narrower than the Zacks Consensus Estimate of a $0.10 loss but wider than the $0.06 loss recorded in the same quarter a year ago. The results came in ahead of revenue estimates.
Why it matters — A Ovid watcher would care because the company's quarterly loss came in better than analyst expectations while also signaling a year-over-year widening in its losses.
Ovid Therapeutics provided business updates and reported its financial results for the second quarter ended June 30, 2026, in a company announcement issued on August 13, 2026. The biopharmaceutical company, focused on brain disorder treatments, detailed these updates via press release.
Why it matters — A Ovid watcher would care because the quarterly financial results and business updates offer an official look at the company's recent operational and financial progress.
The 13 Wall Street analysts covering Ovid Therapeutics, Inc. have a median 12-month price target of $6, with estimates ranging from $4 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 13 analysts covering Ovid Therapeutics, Inc., 13 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ovid Therapeutics, Inc. 66 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Ovid Therapeutics, Inc. ranks 66 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (92 of 100).
No one can know that. What the data says: the median 12-month target from 13 analysts implies +136.2% from the last close, and Ticker Nerd's factor model ranks Ovid Therapeutics, Inc. 66 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Ovid Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OVID are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $9 over the next 12 months.
Ovid Therapeutics, Inc. returned +85.4% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing small molecule medicines for brain disorders, with an emphasis on epilepsies and other seizure-related neurological conditions.
The most recent item we track (PRNewsWire, 15 Oct 2026): "Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer". Actinium Pharmaceuticals announced that Matt David, M.D., has been appointed Chief Financial Officer.
Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing small molecule medicines for brain disorders, with an emphasis on epilepsies and other seizure-related neurological conditions. The company’s current pipeline centers on therapies designed to address significant unmet needs in central nervous system diseases, including OV329, a GABA-AT inhibitor in clinical development, and OV4071, an oral KCC2 activator being studied for select neuropsychiatric and neurological indications. Ovid Therapeutics works at the intersection of drug discovery and clinical development, advancing mechanism-based programs aimed at rare and complex disorders where treatment options remain limited. Its role in the market is to identify differentiated candidates for neurological and neuropsychiatric diseases and progress them through early-stage testing toward potential therapeutic use.
CEO Ms. Margaret Alexander · 23 employees · United States · https://www.ovidrx.com
